SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Coloplast A/S (CLPBF) trades at a trailing P/E of 4.1, forward P/E of 2.6. Trailing earnings yield is 24.63%, forward earnings yield 39.22%. PEG 0.04 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (100/100, Pass) — P/E is below market average (4.1); PEG ≤ 1.0 — Peter Lynch undervalued (0.04); earnings yield beats bond yields (24.63%).
- Forward P/E 2.6 (down from trailing 4.1) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.04 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 24.63% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 39.22% as earnings recover.
Overall SharesGrow Score: 79/100 with 5/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
83/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — CLPBF
Valuation Multiples
P/E (TTM)4.1
Forward P/E2.6
PEG Ratio0.04
Forward PEG0.04
P/B Ratio0.00
P/S Ratio0.53
EV/EBITDA0.0
Per Share Data
EPS (TTM)$16.10
Forward EPS (Est.)$25.65
Book Value / Share$0.00
Revenue / Share$123.45
FCF / Share$0.00
Yields & Fair Value
Earnings Yield24.63%
Forward Earnings Yield39.22%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$14.79 |
$14.68B |
$3.14B |
21.4% |
| 2017 |
$17.87 |
$15.53B |
$3.8B |
24.5% |
| 2018 |
$18.10 |
$16.45B |
$3.85B |
23.4% |
| 2019 |
$18.17 |
$17.94B |
$3.87B |
21.6% |
| 2020 |
$19.68 |
$18.54B |
$4.2B |
22.6% |
| 2021 |
$22.63 |
$19.43B |
$4.83B |
24.8% |
| 2022 |
$22.11 |
$22.58B |
$4.71B |
20.8% |
| 2023 |
$22.19 |
$24.5B |
$4.78B |
19.5% |
| 2024 |
$22.46 |
$27.03B |
$5.05B |
18.7% |
| 2025 |
$16.10 |
$27.82B |
$3.63B |
13% |
